Abeona Therapeutics Inc.
NasdaqCM ABEO
Abeona Therapeutics Inc. Price to Sales Ratio (P/S) on January 14, 2025: 78.57
-
Abeona Therapeutics Inc. 52-week high Price to Sales Ratio (P/S) is 99.54 on January 06, 2025, which is 26.69% above the current Price to Sales Ratio (P/S).
-
Abeona Therapeutics Inc. 52-week low Price to Sales Ratio (P/S) is 15.89 on January 31, 2024, which is -79.77% below the current Price to Sales Ratio (P/S).
-
Abeona Therapeutics Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 54.74.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Dr. Vishwas Seshadri M.B.A., Ph.D. |
| IPO Date | Sept. 19, 1980 |
| Location | United States |
| Headquarters | 1330 Avenue of the Americas |
| Employees | 84 |
| Sector | Health Care |
| Industries | |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Past 5 years
USD 2.25
USD 1.90
USD 1.51
USD 3.17
USD 3.06
USD 4.57
USD 11.16
USD 2.19
USD 3.09
USD 1.60
USD 1.07
USD 7.05
USD 1.39
USD 16.90
USD 1.58
StockViz Staff
January 15, 2025
Any question? Send us an email